J. Safra Sarasin Holding AG Has $4.34 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

J. Safra Sarasin Holding AG trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 36.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,522 shares of the biopharmaceutical company’s stock after selling 5,474 shares during the period. J. Safra Sarasin Holding AG’s holdings in Alnylam Pharmaceuticals were worth $4,342,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. NWF Advisory Services Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $227,000. Kornitzer Capital Management Inc. KS lifted its stake in Alnylam Pharmaceuticals by 2.3% in the third quarter. Kornitzer Capital Management Inc. KS now owns 23,689 shares of the biopharmaceutical company’s stock valued at $10,802,000 after acquiring an additional 525 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Alnylam Pharmaceuticals by 4.4% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 13,985 shares of the biopharmaceutical company’s stock worth $6,380,000 after acquiring an additional 595 shares in the last quarter. Cullen Frost Bankers Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.3% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 11,043 shares of the biopharmaceutical company’s stock worth $5,036,000 after purchasing an additional 248 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 121.2% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 115 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ALNY shares. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. JPMorgan Chase & Co. reduced their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Raymond James Financial reissued an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Bank of America dropped their price target on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $485.21.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 1,510 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the transaction, the executive vice president owned 22,511 shares of the company’s stock, valued at $8,168,566.57. This represents a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,955 shares of company stock valued at $24,072,733 over the last 90 days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.8%

ALNY opened at $354.75 on Wednesday. The company has a market capitalization of $46.87 billion, a P/E ratio of 1,478.13 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm’s fifty day moving average price is $405.78 and its two-hundred day moving average price is $424.53. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.